Evaluation of the circulating fraction of the HER-2/neu oncogene in patients with cervical cancer

European Journal of Gynaecological Oncology

Volumn 23, Issue 6, 2002, Pages 491-495

  Contreras, D N ^b   Cobos, E ^a   Lox, C D ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c NONE

Author keywords

Cervical cancer; HER 2 neu; Serum

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DEATH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA;

ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 0036949918     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Costa M. J., Walls J., Trelford J. D.: "c-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease". Am. J. Clin. Path., 1995, 104.64.
2. Ndubisi B., Sanz S., Lu L., Podczaski E., Benrubi G., Masood S.: "The prognostic value of HER-2/neu oncogene in cervical cancer". Ann. Clin. Lab. Sci., 1997, 27, 396.
3. Mark H. F. L., Feldman D., Das S., Sun C-L., Samy M., Lathrop J.: "HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization". Genet. Test, 1999, 3, 237.
4. Sharma A., Pratap M., Sawhney V. M., Khan I. U., Bhambhani S., Mitra A. B.: "Frequent amplification of c-erebB2 (HER-2/Neu) oncgogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections". Oncology, 1999, 56, 83.
5. Kersemaekeres A. M. F., Fleuren G. J., Kenter G. G., Lambert J., Van Den Brock C. M., Uljee S. M., et al.: "Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis". Clin. Can. Res., 1999, 5, 577.
6. Molina R., Jo J., Filella X., Bruix J., Castells A., Hague M., et al.: "Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases". Tumor Biol., 1997, 18, 188.
7. Cirisano F. D., Karlan B. Y.: "The role of the HER-2/neu oncogene in gynecologic cancers". J. Soc. Gynecol. Invest., 1996, 3, 99.
8. Leitzel K., Teramoto Y., Konrad K., Chincilli V. M., Volgas G., Grossberg H., et al.: "Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer". J. Clin. Oncol., 1995, 13, 1129.
9. Fehm T., Maimonis P., Weitz S., Teramoto Y., Katalinic A., Jager W.: "Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapyy in node-positive breast cancer patients". Breast. Cancer Res. Treat., 1997, 43, 87.
10. Mckenzie J., DeSombre K. A., Bast B. S., Hollis D. R., Whitaker R. S., Berchuck A., et al.: "Serum levels of HER-2/neu (C-erbB-2) correlate with overexpression of p185 in human ovarian. cancer". Cancer. 1993, 71, 3942.
11. Meden H., Marx D., Fattahi A., Rath W., Kron M., Wuttke W. et al.: "Elevated serum levels of c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy". J. Cancer Res. Clin. Oncol., 1994, 120, 378.
12. Zabecky J. R., Lam T., McKenzie S. J., Cerney W.: "The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells SK-BR-3". J. Biol. Chem., 1991, 266, 1716.
13. Meden H., Marx D., Schauer A., Wuttke W., Huhn W.: "Prognostic significance of p1505 (c-erbB-2, HER-2/neu) serum levels in patients with ovarian cancer". Anticancer Res., 1999, 17, 757.
14. Cheung T. H., Wong Y. F., Chung T. K. H., Maimonis P., Chang A. M.: "Clinical use of serum c-erbB-2 in patients with ovarian masses". Gynecol. Obstet. Invest., 1999, 48, 133.
15. Klapper L. N., Glathe S., Vaisman N., Hynes N. E., Andrews G. C., Sela M., et al.: "The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors". Proc. natl. Acad. Sci. USA, 1999, 96, 4995.
16. Bendstein B., Daxenbichler G., Windbichler G., Zeimet A. G., Geurts A., Sweep F., et al.: "Predictive value of PA, PAI-1. HER-2 and VEGF in the serum of ovarian cancer patients". Anticancer Res., 2000, 20, 569.
17. Nijman H. W., Kenemans P., Poort-Keesom R. J., Verstraeten R. A., Mensdorff-Pouilly S., Verheijen S., et al.: "Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer". Eur. J. Obstet. Gynecol. Reprod. Biol., 1999, 83, 201.
18. Nakano T., Oka K., Ishikawa A., Morita S.: "Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma". Cancer, 1997, 79, 513.
19. Volas G. H., Leitzel K., Teramoto Y., Grossberg H., Demers L., Lipton A.: "Serial serum c-erB-2 levels in patients with breast carcinoma". Cancer, 1996, 78, 267.